Overview
My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.
The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.
The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.
Current Appointments & Affiliations
Professor Emeritus of Medicine
·
2013 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Recent Publications
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.
Journal Article Leuk Res · January 2013 PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ... Full text Link to item CiteChronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
Journal Article Leukemia · January 2013 Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that are competent to produce interleukin (IL)-10 (B10 cells). To identify functional links between CLL ... Full text Link to item CiteA phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Journal Article Cancer Chemother Pharmacol · July 2012 PURPOSE: Preclinical data suggest concurrent inhibition of VEGF, mTOR and EGFR pathways may augment antitumor and antiangiogenic effects compared to inhibition of each pathway alone. This study evaluated the maximum tolerated dose/recommended phase II dose ... Full text Link to item CiteRecent Grants
Cancer And Leukemia Group B
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1993 - 1998View All Grants
Education, Training & Certifications
The University of Chicago ·
1967
M.D.